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Abstract 
A family is described with a T ~ G mutation at position 8993 of mtDNA. This mutation is located in the Al'Pase 6 gene of mtDNA 
which encodes ubunit a of the ATP-synthase complex (Fj Fo-ATPase). Clinically, the patients howed severe infimtile lactate acidosis and 
encephalomyopathy in a form that was different from the classical Leigh syndrome. In 3 affected boys, ranging ia age from 3 months to 8 
years, the mutation was found in 95-99% of the mtDNA population. The clinical symptoms correlated with the mtDNA heteroplasmy 
and in the healthy mother 50% of the mtDNA was mutated. The rate of mitochondrial ATP production by cultured skin fibroblasts 
containing 99% of mutated mtDNA was about 2-fold lower than that in normal fibroblasts. Native electrophoresis of the mitochondrial 
enzyme complexes revealed instability of the F]Fo-ATPase in all the tissues of the patient hat were investigated (heart, muscle, kidney, 
liver). Only a small portion of the ATP-synthase complex was present in the complete, intact form (620 kDa). Incomplete forms of the 
enzyme were present as subcomplexes with approx, molecular weights of 460, 390 and 150 kDa, respectively, which differed in the 
content of F~ and F o subunits. Immunochemical nalysis of the subunits of the F~Fo-ATPase further revealed a markedly decreased 
content of the F o subunit b in mitochondria from muscle and heart, and an increased content of the Fo subunit c in muscle mitochondria, 
respectively. These results indicate that in this family the T --* G point mutation at position 8993 in the mitochondrial ATPase 6 gene is 
accompanied by structural instability and altered assembly of the enzyme complex, that are both most likely due to changes in the 
properties of subunit a of the membrane sector part of the ATP-synthase. 
Kevwords: Mitochondrial encephalomyopathy; mtDNA; NARP mutation; Heteroplasmy; ATP-synthase; Fo-subunit 
1. In t roduct ion  
The number of mitochondrial diseases that are based on 
impairment of oxidative phosphorylation is steadily in- 
creasing. Nevertheless, defects of mitochondrial ATP-syn- 
thase, the key enzyme for ATP production in mammalian 
cells appear to be rare. Mitochondrial ATP-synthase con- 
sists of 16 different polypeptides [1], six of which com-  
Abbreviations: mtDNA, mitochondrial DNA; FiFo-ATPase , mito- 
chondrial ATP-synthase; Fo, membrane sector part of ATPase; F], cat- 
alytic part of ATPase; SDS, sodium dodecyl sulfate; PAGE, polyacryl- 
amide gel electrophoresis; PDH, pyruvate dehydrogenase; COX, cy- 
tochrome c oxidase. 
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prise the globular, membrane-extrinsic, Fl-catalytic part 
(subunits a ,  /3, y, 6, e and the inhibitor protein IF I) of 
the enzyme, and the ten others the k[ +-translocating, mem- 
brane-spanning Fo part (a, b, c, d, e, f, g, F6, OSCP and 
A6L). Four of the Fo subunits (OSCP, F6, b, d) form a 
'stalk' which connects the F l and lzo moieties. Only two 
subunits of the F o part - a and A6L - are the products of 
mitochondrial genes [2], the other subunits of the ATP-syn- 
thase are nuclearly encoded. 
Apart from a few cases of deletions of mtDNA that 
include the genes for subunit a and A6L, defects in the 
mitochondrial genes for F o subunits are so far restricted to 
point mutations in subunit a. A point mutation (T --* G) of 
mitochondrial DNA at nucleotide 8993 which causes re- 
placement of a Leu ~ Arg has been found in several 
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families with individuals uffering from neurogenic muscle 
weakness, ataxia, and retinitis pigmentosa (NARP) [3,4] or 
Leigh's syndrome [5-8]. Another point mutation (T ~ C) 
at the same locus was detected by De Vries et al. [9]. The 
consequence of the mutation is a decrease in mitochondrial 
ATP production [10,11], possibly on the basis of dysfunc- 
tion of the F o proton channel which is formed by both 
subunit c and subunit a. The hypothesis that the change of 
the highly conserved leucine at position 156 in subunit a 
into a positively charged arginine directly disturbs the 
function of the proton channel and thus the formation of 
ATP [10,11] was further supported by site-directed muta- 
genesis of the analogous ubunit in the bacterial enzyme 
[121. 
We identified a family in which the T ~ G mutation at 
position 8993 was associated with severe clinical symp- 
toms that differed in a number of respects from the NARP 
or Leigh syndrome. Studies in cultured fibroblasts from the 
patient clearly showed a reduced capacity for mitochon- 
drial ATP synthesis. In addition, investigations in several 
tissues from one of the patients demonstrated that this 
mutation in ATPase 6 gene is also accompanied by altered 
structural properties of the enzyme. In preliminary form 
part of this work has been published before [13]. 
2. Patients 
Patients 1-3 from a family with point mutation at 8993 
position of mtDNA are a boy (3) who died at the age of 
3.5 months, his sister (2) who died at the same age, and 
their alive, 8-years-old brother (1); they were described by 
Klement et al. [13]. They all had severe infantile lactate 
acidosis and encephalomyopathy at was different from 
classical Leigh syndrome. Recently, the fourth child (4) of 
this family was born. The boy showed progressive hypoto- 
nia since birth and developed seizures and apnoeic spells 
at the age of 3 months. Serum and liquor lactic acid levels 
were increased (4.4-8 mM lactate, lactate/pyruvate 17). 
He was transferred to the intensive care unit of the Depart- 
ment of Pediatrics and artificially ventilated because of 
respiratory failure. He had no symptoms of infection. 
Clinically, he improved after treatment with sodium 
dichloroacetate (10-50 mg/kg per day). He was dismissed 
from the hospital and is presently at home care, but 
psychomotoric retardation persists. Both parents and 
grandparents of these children are healthy. Skin biopsies 
and analysis of autopsy material were performed after 
informed consent had been granted. 
3. Materials and methods 
3.1. Cell culture 
Skin fibroblasts from forearm biopsies were routinely 
cultured in a humidified CO 2 atmosphere (5%) in D-MEM 
supplemented with 10% foetal calf serum. Confluent cells 
were harvested by scraping with a rubber policeman in 250 
mM Sucrose, 10 mM Tris-HC1, 1 mM EDTA, pH 7.4, 
(STE). The cells were homogenised using a Teflon-glass 
homogenizer and frozen in portions at - 70 ° C. 
3.2. Tissues 
Samples of liver, heart, muscle, kidney and brain au- 
topsy material obtained within 3 h after death were imme- 
diately frozen in liquid nitrogen for later isolation of DNA 
and the preparation of homogenates. 
3.3. Mitochondria 
Approx. 1 g of fresh samples of liver and heart were 
used for isolation of mitochondria in STE buffer [14]. 
Mitochondria from muscle were isolated in KC1 medium 
(150 mM KC1, 50 mM Tris-HC1, 2 mM EDTA, pH 7.4) 
from 10% homogenates (using a hand driven glass-glass 
Dounce homogenizer) according to the procedure of Maki- 
nen and Lee [15], but without he use of proteases. 
3.4. Enzyme assays 
Pyruvate dehydrogenase (PDH) was measured in tissue 
homogenates according to Teodosiu et al. [16] and in 
fibroblasts according to Sperl et al. [17]. Cytochrome c
oxidase (COX) activity was measured as described by 
Wharthon and Tzagoloff [18] using 25 /xM reduced cy- 
tochrome c. Succinate cytochrome c oxidase and NADH 
oxidase activity were measured according to Fisher et al. 
[t9,20], and NADH cytochrome c reductase as described 
by Sottocasa et al. [21]. The protein content of the samples 
was measured according to Lowry et al. [22]. 
3.5. ATP  synthesis 
The rate of ATP synthesis by digitoninized cultured 
skin fibroblasts was measured as described by Wanders et 
al. [23]. After harvesting by trypsinisation, the PBS-washed 
fibroblasts were resuspended in 150 mM KC1, 25 mM 
Tris-HC1, 2 mM EDTA, 1 mM ADP, 10 mM K-Pi, 0.1% 
BSA, pH 7.4 at a concentration f 0.16 mg/ml, subjected 
to 40 /zg digitonin/ml and incubated in the presence of 
NADH-linked respiratory substrates (pyruvate + malate, 
glutamate + malate or 2-oxoglutarate + malate) or succi- 
nate+ rotenone for 30 min at 37 ° C. The ATP produced by 
the fibroblasts was measured fluorometrically [24]. The 
rate of ATP production is expressed as nmol/30 min per 
mg protein. The values were corrected for the production 
of ATP in the presence of antimycin. The final concentra- 
tions of the various substrates were 10 raM, and that of the 
inhibitors 2 /xg/ml. 
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3.6. Western blot analysis 
PDH, COX and F~-ATPase content were determined 
using Tricine-SDS-PAGE according to Sch~igger and Von 
Jaggow [25] followed by semidry-blotting of proteins on to 
Hybond C-extra membrane (Amersham) according to Bjer- 
rum and Schafer-Nielsen [22]. Previously described [26-29] 
specific antisera to Fi-ATPase, subunits b and c of F o (b-F,, 
and c-Fo), subunits of COX and the El c~ component of 
PDH were used at titters of 1:2000-10000. Immunocom- 
plexes were detected using a peroxidase-conjugated sec- 
ondary antibody (FAB fragment 1:3000; Bio-Rad) and 
chemiluminescence (ECL-Amersham). Several concentra- 
tions of protein were used for the semiquantitative d termi- 
nation of the content of the various mitochondrial proteins. 
The data were evaluated using an ULTROSCAN XL laser 
densitometer (LKB), or a Personal Densitometer (Molecu- 
lar Dynamics), and are expressed in arbitrary units (AU). 
3.7. Blue natil~e electrophoresis 
Native electrophoresis of mitochondrial enzymes was 
performed according to Sch~.gger and Von Jagow [30]. A 
non-linear 6-15% polyacrylamide gradient was used to 
resolve the individual mitochondrial respiratory chain com- 
plexes and the F1Fo-ATPase. Prior to electrophoresis, the 
mitochondrial pellet was resuspended (5 mg protein/ml) 
in 750 mM 6-amino-n-caproic a id, 50 mM Bis-Tris-HCl, 
pH 7.4, 0.5 mM EDTA and 1% lauryl maltoside. The 
samples were incubated on ice for 15 min and then cen- 
trifuged at 20000 × g for 20 rain. The protein content of 
the supematants was measured by the method of Bradford 
[31]. Serva Blue G dissolved in 750 mM 6-amino-n-caproic 
acid, was added to the supernatants o a final concentration 
of 0.25%. 10-15 /zg of protein was loaded on to the first 
dimension slab gels. These slab gels were either stained by 
Coomassie Brilliant Blue R, or analysed by Western blot- 
ting. Stripes of the first dimension gel containing the 
separated protein complexes were cut out, incubated with 
1% SDS and 1% mercaptoethanol f r 1 h at room tempera- 
ture and subjected to 10% Tricine-SDS-PAGE for analysis 
in the second dimension as described by Sch~igger and 
Von Jagow [25,30]. 
AMC, Amsterdam, The Netherlands) was carried out 
overnight. After hybridization, the membranes were ex- 
posed for 24 h to films or for 6 h to screens of a 
Phosphorimager (Molecular Dynamics). 
4. Results 
Fig. 1 shows the results of Southern blot analysis of 
mtDNA isolated from various tissues of the patient 3. In 
comparison with normal mtDNA, two additional restriction 
fragments with a size of 0.8 and 0.2 kb, respectively, were 
found in the patient after digestion with HpaII. This 
together with an equal restriction pattern obtained with 
AcaI (not shown) indicated the presence of an abnormal 
restriction site that is due to the 8993 mutation which has 
been described before in other case~ [3,11 ]. It is clear that 
this patient has a generalised efect: tissues as different in 
ontogenic origin as the central nervous system and fibrob- 
lasts are equally affected. The ratio of mutated and normal 
mtDNA was higher than 98% in all tissues as revealed by 
densitometry of the autoradiographs 
(kb) 
2.0 
1.0 
0.8 
0.2 
3.8. DNA analysis 
Isolation of total DNA, electrophoresis of DNA frag- 
ments on agarose gels and Southern blotting were per- 
formed according to standard procedures [32]. After diges- 
tion by HpalI or AcaI, DNA aliquots (3 /zg) were elec- 
trophoresed on 1.1% or 0.7% agarose gels and blotted on 
to Hybond N membrane (Amersham). Hybridization with 
32p-ATP-labeled mtDNA probes, covering the regions 
8592-9648 (HpaII  digested DNA) or 11922-12641 ( AvaI 
digested samples) (kindly provided by Dr. P. Bolhuis, 
FF  FBKH LH L 
I II I Patientl Patient , I 
Control Control 
Fig. 1. Southern blot analysis of mtDNA fiom difterent tissues of the 
patient. 3 p,g aliquots of total DNA isolated from fibroblasts (F), brain 
(B), kidney (K), heart (H) or liver (L) were digested with HpaII. After 
electrophoresis on agarose gels and blottini~, on to nylon membranes. 
hybridization was performed with a probe co,,ering the 8592-9648 region 
of mtDNA. Two bands were detected incontrol samples, but three in the 
patient 3, where a new restriction site was present on a 1.1 kb fragment 
(8150-9292) as the result of the 8993 mutation. Detection was performed 
by autoradiography on X-OMAT Kodak film. 
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The results of  genetic analysis of the family are shown 
in Fig. 2. The frequency and distribution of  the mutation 
within the family was investigated in mtDNA isolated 
from leukocytes and/or  fibroblasts using restriction site 
polymorphism for Ava I .  Evaluation of  the data was done 
by phosphor imaging. Both leukocytes and fibroblasts of  
the two youngest and severely affected brothers (patients 3 
and 4) showed more than 99% of mutated mtDNA.  A very 
high percentage of mutated mtDNA was also found in the 
leukocytes of  the oldest boy (patient 1) where normal 
mtDNA comprised as little as 4% of the total mtDNA 
content. Mutated mtDNA in fibroblasts and leukocytes 
from the mother accounted for 50% of the total. No 
mutated mtDNA was detected in leukocytes of the father. 
Enzymological  analysis was carried out in different 
tissues of  the patient 3. PDH activity was normal in liver, 
muscle and heart mitochondria nd also in fibroblasts. The 
activities of  the enzymes of the respiratory chain were also 
within the control range. Western blot analysis revealed a 
normal content of  COX,  PDH and F1-ATPase in ho- 
mogenates of  muscle (AU/mg protein in patient and 
control: COX - 0 .60+0.07  and 0 .43_0 .17 ;  PDH - 
2.26 4- 0.29 and 1.62 _+ 0.41; ATPase - 0.71 _+ 0.08 and 
0.83 _+0.13) and heart (AU/mg protein in patient and 
6oo[ 
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£ 
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o 
E 
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Control Glu+Mal Pyr+Mal Og+Mal Succ+Rot 
Fig. 3. ATP synthesis by digitonized cultured skin fibroblasts. Cells were 
incubated with the indicated substrates and inhibitors at 37 ° C for 30 min 
and the amount of ATP produced was measured fluorometrically. The 
data are mean + S.E. values of six independent experiments performed in 
duplicate. Gin + Mal - glutamate +malate; Pyr + Mal - pyruvate +malate; 
Og + Mal - oxoglutarate + malate; Succ + Rot - succinate +rotenone. 
Patient 4 - black bars; mother - gray bars; control - empty bars. 
* 99% 99% 96% 0% 50% 50% 0% 
14.4 kb - -  
4.0 kb 
Leu Fib Leu Fib Leu Fib Leu 
i 4 3 11 I 
Patients Control Mother Father 
Fig. 2. Pedigree and restriction fragment analysis of mtDNA in the family with the 8993 mutation. 3 /zg aliquots of total DNA isolated from leukocytes 
(Leu) or fibroblasts (Fib) were digested with Anal. After electrophoresis onagarose gels and blotting on to nylon membranes, hybridization was performed 
with a probe covering the 11922-12641 region of mtDNA. One 14.6 kb fragment was detected in controls. An additional fragment of 0.4 kb was present in 
the patients 1, 3 and 4 due to a new restriction site at position 8993. The ratio of mutated and normal mtDNA as indicated at the top is given in % of 
mutated mtDNA and was calculated from the phosphor-imaging analysis of the blot. * - not available. 
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Table 1 
Ratio between the content of different subunits of ATPase in mitochondria solated from patient and control heart and muscle 
353 
Ratio between Heart Muscle 
ATPase subunits Patient Control Patient C ontrol 
b-Fo/~ +/3 F t 0.26 _+ 0.10 1.0 _+ 0.18 0.51 +_ 0.03 1.0 + 0.07 
c-Fo/o~ +/3 F~ 1.12 + 0.13 1.0 + 0.17 3.70 _+ 0.07 10 _+ 0.14 
2.5-7.5 /xg protein aliquots were analysed for the content a +/3 subunits of F I (c~ +/3 F I), subunit b of Fo (b-F o) and subunit c of Fo (c-F o) by Western 
blotting as indicated in Fig. 6. The data represent the mean + S.E. of duplicate values obtained at different concentrations of protein. The ratio of F o and F t 
subunits is arbitrarily set at 1 for each control tissue. 
control: COX - 0.59 +0.07 and 0 .70_  0.07; PDH - 
1.02 + 0.13 and 1.26 ___ 0.05; ATPase - 1.54 + 0.13 and 
1.24 _ 0.13). 
The rate of mitochondrial ATP synthesis, measured in 
digitoninized fibroblasts of the youngest child (patient 4) 
which contained 99% of mutated mtDNA (both in leuko- 
cytes and in fibroblasts) was impaired to about 50%, 
regardless of the substrates used to induce oxidative phos- 
phorylation (glutamate + malate, pyruvate + malate, 2- 
oxoglutarate + malate or succinate + rotenone) (Fig. 3). 
Coomassie Blue staining 
(kDa 
670 
440 
230 
140 
67 
Heart mitochondria 
I 15ug 10ug I 
I I I I I 
F1-ATPase immunoblot 
I (ATPaze) - 
III 
460  kDa - -  
390 kDa - -  
IV 
55kDa ..... 
Heart mitochondria 
I10ug 15ug I 
a. o 
I I I 
Fig. 4. Native electrophoresis of heart mitochondria. 10 and 15 /zg protein aliquots of control and patient heart mitochondria were solubilised by lauryl 
maltoside and subjected to blue-native PAGE (6-15% gradient polyacrylamide) asdetailed in Section 2. One part of the gel was stained with Coomassie 
Brilliant Blue (left panel), the other part was analysed by Western blotting (right panel) with anti F~-ATPase antibody (I:100(~). The position of NADH 
dehydrogenase (I), bc I complex (III), cytochrome c oxidase (IV), ATPase (V) and of molecular weight standards (MWS) as well as the position of ATPase 
subcomplexes with apparent molecular weights of 460 kDa, 390 kDa and 55 kDa, respectively, that were found in patient's mitochondria, is indicated. 
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Fibroblasts of the mother that contained 50% of mutated 
mtDNA showed only slightly decreased ability to produce 
ATP (70-93% of control, Fig. 3). 
Native electrophoresis of detergent-solubilised mito- 
chondria isolated from heart tissue of the patient (3) 
showed a normal content of the respiratory chain com- 
plexes I, III and IV, but a markedly decreased amount of 
fully assembled ATP-synthase (complex V, apparent 
molecular weight 620___ 15 kDa) (Fig. 4). Instead, addi- 
tional bands with approx, molecular weights of 460 + 12 
kDa and 390 ___ 15 kDa, respectively, were seen on stained 
gels (Fig. 4, left panel), close below the position of 
complex III (apparent molecular weight 520 ___ 15 kDa). 
Immunochemical nalysis (Fig. 4, right panel) confirmed 
the decreased amounts of normally sized FIFo-ATPase 
molecules in the samples from the patient. Moreover, it 
showed that the two additional bands contained F~ subunits 
and represented subcomplexes of the enzyme. Of the total 
amount of Fl-immunoreactive material less than 20% was 
present at the position of a normal, intact ATPase com- 
plex. The same results were obtained when other tissues of 
the patient were analysed (liver, muscle, kidney, brain). 
The additional band of 460 kDa was entirely unique for 
the patient issues and contained about 25% of the total F E- 
antigen. The band of 390 kDa representing most likely the 
complete Fi-ATPase part, was also present in control 
mitochondria but only in minute amounts. In contrast, the 
band of 390 kDa represented almost 40% of the total 
immunoreactive material in the patient. Remaining Fj-im- 
munoreactive material was present close to the front of the 
gel (apparent molecular weight 55 kDa), this material 
could represent individual ce and /3 subunits. 
Further analysis of the oxidative phosphorylation com- 
plexes after electrophoresis in the second dimension by 
Heart 
mitochondria 
Native PAGE of heart mitochondria 
Patient 
13> 
,. ~ V (AlPase) 
o o  1 O a_ 460 kDa 150 kDa 
[ I I r '39°  kDa I 
Control 
V (ATPase) 
390 kDa 
55 kDa 
, I 55 kDa I 
F1 1~-- 
b-F0-- 
c_F0 - -  
O 
Q 
V (ATPase) 
I <390kOa t I 
460 kDa 150 kDa 
V (ATPase) 
60 
60 
:o 
m 
Fig. 5. Immunodetection f F I and F o subunits in subcomplexes of ATPase. 15 ~g aliquots of patient (central panel) and control (right panel) heart 
mitochondria were separated in the first dimension by blue-native PAGE and in the second dimension by Tricine-SDS-PAGE as detailed in Section 2, or 
by Tricine-SDS-PAGE only (left panel). Western blot analysis was performed with antibody to Fi-ATPase (1:10000, upper part of the gels), and 
antibodies to subunit b of F o (b-F o, 1:5000, middle part of gels), or subunit c of F o (C-Fo, 1:750, bottom part of the gels). The position of the full-size 
ATPase complex (V) and of subcomplexes with apparent MW 460 kDa, 390 kDa, 150 kDa and 55 kDa, is indicated. 
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Fig. 6. Western blot analysis of heart and muscle mitochondria of the 
patient. 5 k~g protein aliquots of isolated mitochondria were analysed by 
Tricine-SDS-PAGE and Western blotting using specific antisera to F I- 
ATPase, subunit b of F o (b-F o) and subunit c of Fo (c-F o) as described in 
Fig. 6, and to cytochrome c oxidase (COX, 1:2000). 
staining or Western blotting (Fig. 5) revealed the presence 
of subunits a and [3 in stoichiometric amounts in the 390 
kDa subcomplex both in the patient and in the control. 
These F~ subunits were also present in the 460 kDa 
subcomplex. Subunit c, the most numerous ubunit of F o, 
was clearly detected in fully sized ATPase as well as in the 
460 kDa subcomplex of the patient, but was hardly present 
in the 390 kDa subcomplex. Subunit c in control material 
was almost entirely present in intact ATPase of the normal 
size. In contrast, most of subunit c in the patient (about 
55%) was found in the region of proteins with an apparent 
molecular weight around 150 kDa. The content of subunit 
b of the F o part was decreased in the patient on first 
dimension gels and was barely visible on the gel of the 
second dimension. 
When the total content of F r and Fo subunits of ATP- 
synthase in the tissues of the patient was investigated by 
one-dimensional SDS-PAGE and Western blotting of tis- 
sue homogenates, no significant difference was found be- 
tween the patient and controls in the content of either F~ 
subunits or of F o subunits b an c. However, in mito- 
chondria isolated by differential centrifugation from tissues 
of the patient (Fig. 6), the content of subunit b and subunit 
c differed from that in control mitochondria, but the con- 
tent of F~ subunits and COX subunits was the same. The 
content of subunit b in muscle mitochondria was decreased 
to 50% of the control, while the content of subunit c was 
3-4 times higher than in the control (Table 1). In heart 
mitochondria similar difference between patient and 
control was detected for subunit b. Accordingly, part of the 
content of subunit b, or of its immunoreactive r gion, was 
lost during preparation of mitochond:da from tissues of the 
patient, and vice versa, the content of subunit c, the most 
hydrophobic protein of the inner membrane, was relatively 
increased. 
5. Discussion 
Our data provide detailed clinical, biochemical and 
genetic information about severely affected patients from a 
family in which we found a mutation at position 8993 of 
mtDNA. Some particular features were the absence of 
Leigh syndrome, the early onset ol f the disease and its 
rapid progression [13]. We also found a relationship be- 
tween the amount of mutated mtDNA and the clinical 
severity of the disease, in accorda~Lce with other recent 
studies [11 ]. The 8993 mutation can apparently be associ- 
ated with completely distinct clinical manifestations re- 
garding the onset and duration of the disease. The impor- 
tant protective ffect of the residual wild type mtDNA is 
illustrated by the different clinical course of the oldest 
brother in comparison to his younger siblings. Hardly any 
normal mtDNA was detected in the case of two youngest 
brothers (less than 1%, within the accuracy of the method) 
while 4% of normal mtDNA, as found in the oldest brother 
apparently led to a milder expressien of the disease and 
longer survival. An alternative xplanation could be based 
on the influence of other genetic or environmental factors. 
The significantly decreased capacity of the fibroblasts 
from the patient to synthesise ATP clearly shows the 
functional significance of the mutation for oxidative phos- 
phorylation. This finding is in line with the data of Tatuch 
et al. [10,11 ], who demonstrated a similar decrease in ATP 
production in mitochondria isolated from lymphoblasts of 
their patient, as well as with findings of Hartzog and Cain 
[12], who used a bacterial model in which an analogous 
mutation in subunit 6 was created. The defect in ATP 
synthesis is not directly proportional to the percentage of 
mutated mtDNA; even a few copie:~ of normal mtDNA 
result in a significant ability to synthesise ATP, similarly 
as noted by Tatuch et al. [11]. The lack of correlation 
between the percentage of mutated mtDNA and ATP 
synthesis is also apparent from our ~tudies in the fibrob- 
lasts of the healthy mother. 
The low content of normally-sized FiFo-ATPase, the 
presence of an atypical 460 kDa complex and the abundant 
presence of a 390 kDa complex can be explained by a 
decreased stability of the enzyme in the patient. The 390 
kDa complex is most likely Fj-ATPase, while the 460 kDa 
356 J. Hougtgk et al. / Biochimica et Biophysica Acta 1271 (1995) 349-357 
complex represents F1-ATPase assembled with some F o 
subunits, including subunit c. These subcomplexes may 
result from a disturbed connection between F~ and Fo 
domains, or be ascribed to an abnormal assembly or lower 
stability of Fo. Assuming that this is primarily caused by 
the mutation in subunit a, there is again a lack of correla- 
tion between the percentage of mutated mtDNA and the 
percentage of altered ATP-synthase complexes. Together 
with the data about ATP synthesis this indicates that the 
ATP-synthase molecules containing mutated subunit a, or 
mutated subunit a itself are more susceptible to degrada- 
tion in vivo. 
The selective decrease of the amount of subunit b in 
mitochondria solated from tissues of the patient might be 
due to an insufficient protection by attached Fl against 
proteolytic degradation, in a similar way as was described 
for mitochondrial [27] and bacterial [33] membranes from 
which Fj was stripped off. This would also implicate that 
the change in mutated subunit a affects the protein-protein 
interactions with other F o subunits, in particular with sub- 
unit b. Consequently, the link between F1 and F o domains 
might be impaired in the 'stalk' region in which subunit b 
plays a crucial role [1]. The higher content of subunit c in 
muscle of the patient and its atypical ocation on second 
dimension gels indicate also a decreased affinity of F o to 
bind F I. 
The oligomycin sensitive ATPase activity was normal 
in some patients with the mtDNA 8993 mutation [5] and 
no difference in the content of immunodetectable F~ sub- 
units was observed [13]. However, mitochondrial ATP 
synthesis was clearly impaired in vitro (present results and 
[11]) and in bacteria with a comparable mutation [12]. 
Therefore, it is highly likely that the mutation severely 
affects the normal function of the proton channel [11,12]. 
In addition, our data indicate that the mutation disturbs the 
structural integrity of the enzyme at the level of F~ interac- 
tions with F o. The properties of the ATP-synthase complex 
clearly differed in the patient and resulted in a lower 
stability and/or abnormal assembly of the enzyme. Such 
changes will undoubtedly decrease the capacity for oxida- 
tive phosphorylation and might thus contribute to the 
severity of the disease. 
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